Evidence map›Paper›PMID 34237209›Full record

ArticleCancer research and treatment2022

Clinicopathologic Characteristics and Clinical Outcome of Localized Liposarcoma: A Single-Center Experience over 25 Years and Evaluation of PD-L1 Expression.

Heejung Chae, Jeong Eun Kim, Wanlim Kim, Jong-Seok Lee, Si Yeol Song, Min Hee Lee, Hye Won Chung, Kyung-Ja Cho, Joon Seon Song, Jin-Hee Ahn

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Heejung ChaeDepartment of Oncology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea.
Jeong Eun KimDepartment of Oncology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea.
Wanlim KimDepartment of Orthopedic Surgery, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea.
Jong-Seok LeeDepartment of Orthopedic Surgery, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea.
Si Yeol SongDepartment of Radiation Oncology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea.
Min Hee LeeDepartment of Radiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea.
Hye Won ChungDepartment of Radiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea.
Kyung-Ja ChoDepartment of Pathology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea.
Joon Seon SongDepartment of Pathology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea.
Jin-Hee AhnDepartment of Oncology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea.
Asan Medical Center · KRUlsan College · KRUniversity of Ulsan · KR

Funding

Asan Cancer Institute of Asan Medical CenterAsan Institute for Life Sciences, Asan Medical Center 2018-0570
6 · The paper itself

Abstract

purposeFor liposarcoma (LPS), clinical course and proper treatment strategies have not been well-established. Recently, immune-checkpoint inhibitors have shown potential efficacy in LPS. We aimed to describe the clinical course of LPS and evaluate the clinical impact of programmed death-ligand 1 (PD-L1). MATERIALS AND

methodsWe reviewed all consecutive patients (n=332) who underwent curative-intent surgery for localized LPS at Asan Medical Center between 1989 and 2017. PD-L1 testing was performed in well-differentiated and dedifferentiated LPS.

resultsThe median age was 56 years with males comprising 60.8%. Abdomen-pelvis (47.6%) and well-differentiated (37.7%) were the most frequent primary site and histologic subtype, respectively. During a median follow-up of 81.2 months, recurrence was observed in 135 (40.7%), and 86.7% (117/135) were loco-regional. Well-differentiated subtype (hazard ratio [HR], 0.38), abdomen-pelvis origin (HR, 2.43), tumor size larger than 5 cm (HR, 1.83), positive resection margin (HR, 2.58), and postoperative radiotherapy (HR, 0.36) were significantly related with recurrence-free survival as well as visceral involvement (HR, 1.84) and multifocality (HR, 3.79) in abdomen-pelvis LPS. PD-L1 was positive in 31.5% (23/73) and 51.3% (39/76) of well-differentiated and dedifferentiated LPS, respectively, but had no impact on survival outcomes.

conclusionClinical course of LPS was heterogeneous according to histology and anatomic location. Clear resection margin was important to lower recurrence and postoperative radiotherapy might have additional benefit. A decent portion of well-differentiated and dedifferentiated LPS were positive for PD-L1, but its prognostic role was unclear. Further research is needed to determine clinical implications of PD-L1, especially for advanced-stage LPS with unmet needs for effective systemic treatment.

Indexed as

B7-H1 AntigenLiposarcomaDisease-Free SurvivalFemaleHumansLipopolysaccharidesMaleMargins of ExcisionMiddle AgedPrognosisB7-H1 AntigenCD274 protein, humanLipopolysaccharidesImmunotherapyLiposarcomaPrognosisProgrammed death-ligand 1Retrospective analysisSarcoma

Identifiers

PMID34237209
PMCPMC9016292
OpenAlexW3181621042

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.